Gotowa bibliografia na temat „Prédictions des complications du diabète”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Prédictions des complications du diabète”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Prédictions des complications du diabète"
Omoola, O. O., A. A. Tijani, A. A. Okesina, E. G. Anyanwu i U. M. Ibe. "Significance of anthropometric parameters in the prevalence of type 2 diabetes- a case study of selected hospitals in western Uganda". Research Journal of Health Sciences 12, nr 1 (12.02.2024): 53–61. http://dx.doi.org/10.4314/rejhs.v12i1.7.
Pełny tekst źródłaMillot, F., B. Fautrel i S. Rozenberg. "Complications ostéoarticulaires du diabète". EMC - Endocrinologie - Nutrition 6, nr 3 (styczeń 2009): 1–9. http://dx.doi.org/10.1016/s1155-1941(09)51219-x.
Pełny tekst źródłaThiolet, C., D. Corberand, F. Harnois, D. Mennecier i O. Farret. "Complications digestives du diabète". EMC - Gastro-entérologie 3, nr 1 (styczeń 2008): 1–8. http://dx.doi.org/10.1016/s1155-1968(08)27498-5.
Pełny tekst źródłaFautrel, Bruno. "Complications musculosquelettiques du diabète". Revue du Rhumatisme Monographies 78, nr 4 (wrzesień 2011): 239–45. http://dx.doi.org/10.1016/j.monrhu.2011.07.001.
Pełny tekst źródłaSaïd, G. "Complications neurologiques du diabète". EMC - Traité de médecine AKOS 5, nr 2 (styczeń 2010): 1–8. http://dx.doi.org/10.1016/s1634-6939(10)52303-2.
Pełny tekst źródłaNathan, D., i P. Cleary. "Diabète et complications cardiovascularies". Revue Francophone des Laboratoires 2006, nr 380 (marzec 2006): 14. http://dx.doi.org/10.1016/s1773-035x(06)80104-8.
Pełny tekst źródłaVacheron, André. "Complications cardiovasculaires du diabète". Bulletin de l'Académie Nationale de Médecine 195, nr 1 (styczeń 2011): 205–11. http://dx.doi.org/10.1016/s0001-4079(19)32118-1.
Pełny tekst źródłaÉmile, Carole. "Dépistage des complications du diabète". Option/Bio 29, nr 597-598 (maj 2019): 27–29. http://dx.doi.org/10.1016/s0992-5945(19)30118-7.
Pełny tekst źródłaA., F. "AGEs et complications du diabète". Médecine des Maladies Métaboliques 9, nr 1 (luty 2015): 64. http://dx.doi.org/10.1016/s1957-2557(15)30013-4.
Pełny tekst źródłaORBAN, J., i C. ICHAI. "Complications métaboliques aiguës du diabète". Réanimation 17, nr 8 (grudzień 2008): 761–67. http://dx.doi.org/10.1016/j.reaurg.2008.09.006.
Pełny tekst źródłaRozprawy doktorskie na temat "Prédictions des complications du diabète"
Toofanee, Mohammud Shaad Ally. "An innovative ecosystem based on deep learning : Contributions for the prevention and prediction of diabetes complications". Electronic Thesis or Diss., Limoges, 2023. https://aurore.unilim.fr/theses/nxfile/default/656b0a1f-2ff2-49c5-bb3e-f34704d6f6b0/blobholder:0/2023LIMO0107.pdf.
Pełny tekst źródłaIn the year 2021, estimations indicated that approximately 537 million individuals were affected by diabetes, a number anticipated to escalate to 643 million by the year 2030 and further to 783 million by 2045. Diabetes, characterized as a persistent metabolic ailment, necessitates unceasing daily care and management. In the context of Mauritius, as per the most recent report by the International Diabetes Federation, the prevalence of diabetes, specifically Type 2 Diabetes (T2D), stood at 22.6% of the population in 2021, with projections indicating a surge to 26.6% by the year 2045. Amidst this alarming trend, a concurrent advancement has been observed in the realm of technology, with artificial intelligence techniques showcasing promising capabilities in the spheres of medicine and healthcare. This doctoral dissertation embarks on the exploration of the intersection between artificial intelligence and diabetes education, prevention, and management.We initially focused on exploring the potential of artificial intelligence (AI), more specifically, deep learning, to address a critical complication linked to diabetes – Diabetic Foot Ulcer (DFU). The emergence of DFU poses the grave risk of lower limb amputations, consequently leading to severe socio-economic repercussions. In response, we put forth an innovative solution named DFU-HELPER. This tool serves as a preliminary measure for validating the treatment protocols administered by healthcare professionals to individual patients afflicted by DFU. The initial assessment of the proposed tool has exhibited promising performance characteristics, although further refinement and rigorous testing are imperative. Collaborative efforts with public health experts will be pivotal in evaluating the practical efficacy of the tool in real-world scenarios. This approach seeks to bridge the gap between AI technologies and clinical interventions, with the ultimate goal of improving the management of patients with DFU.Our research also addressed the critical aspects of privacy and confidentiality inherent in handling health-related data. Acknowledging the extreme importance of safeguarding sensitive information, we delved into the realm of Peer-to-Peer Federated Learning. This investigation specifically found application in our proposal for the DFU-Helper tool discussed earlier. By exploring this advanced approach, we aimed to ensure that the implementation of our technology aligns with privacy standards, thereby fostering a trustworthy and secure environment for healthcare data management.Finally, our research extended to the development of an intelligent conversational agent designed to offer round-the-clock support for individuals seeking information about diabetes. In pursuit of this goal, the creation of an appropriate dataset was paramount. In this context, we leveraged Natural Language Processing techniques to curate data from online media sources focusing on diabetes-related content
Garnier, Laurent. "Etude du bénéfice à court et moyen terme d'une mise en normoglycémie stricte chez 72 patients diabétiques non insulino-dépendants : recherche de facteurs prédictifs". Bordeaux 2, 1995. http://www.theses.fr/1995BOR2M103.
Pełny tekst źródłaPotier, Louis. "Rôle du système kallicréine-kinines dans le diabète et ses complications". Phd thesis, Université Pierre et Marie Curie - Paris VI, 2014. http://tel.archives-ouvertes.fr/tel-00990006.
Pełny tekst źródłaDesposito, Dorinne. "Rôle du système kallicréine-kinine(s) dans les complications du diabète". Thesis, Paris 6, 2015. http://www.theses.fr/2015PA066258/document.
Pełny tekst źródłaThe kallikrein-kinin(s) system (KKS) is a peptide system with various pathophysiological effects. Kinins exert their actions through activation of two different receptor subtypes: B1 receptor (B1R) and B2 receptor (B2R). The aim of my thesis was to study the role of this system in diabetic complications in mice. We used pharmacological approaches using new specific agonists of B1R or B2R, or a specific antagonist of B2R. In the first part, we showed that selective pharmacological activation of B1R or B2R overcomes the effect of diabetes on post-ischemic neovascularization and restores tissue perfusion through inflammation. In a second model, we showed that B2R agonist impairs wound repair in mice, inducing skin disorganization and epidermis thickening. Interestingly, B2R blockade improves skin wound healing in two mouse models of diabetes. In a last part, we showed that B2R activation increases mortality after transient cerebral ischemia. In diabetic mice, B1R activation has neuroprotective effects. Indeed, B1R agonist treatment decreases infarct size and improves neurological deficit at day 2 after transient cerebral ischemia. To conclude, KKS activation has contradictory effects depending on the organs studied. The study of new B1 or B2 kinin receptor agonists opens new therapeutic options in diabetic complications
Pascual, Luc. "Aspects épidémiologiques des complications du diabète dans une population de diabétiques camerounais". Bordeaux 2, 1996. http://www.theses.fr/1996BOR2M137.
Pełny tekst źródłaLiuu, Evelyne. "Cancer, diabète et complications vasculaires : approche épidémiologique de cohortes oncogériatrique et diabétique". Thesis, Poitiers, 2020. http://www.theses.fr/2020POIT1408.
Pełny tekst źródłaIncreases of cancer incidence and mortality are a major public health issue, accentuated by population aging. Among the age-related comorbidities, we wanted to specify the burden of diabetes, in particular type 2 (T2D) due to, like cancer, its high prevalence in older population and its multi-system consequences. This work explores the relationship between diabetes, its vascular complications (VC) and cancer, with a particular interest in the geriatric setting. This thesis is based on several finalized and ongoing publications:Article 1: Comprehensive geriatric assessment in older patients with cancer: an external validation of the multidimensional prognostic index in a French prospective cohort study. BMC Geriatr. 2020; 20: 295. doi: 10.1186 / s12877-020-01692-8Heterogeneity of health status in older age claims for the identification of frailty factors influencing life expectancy during oncological diagnosis and follow-up. The geriatric oncology assessment identifies frailty of older patient with cancer. We evaluated the impact of co-morbidities on life expectancy. This geriatric oncology study involved 433 patients included for two years (42% women; mean age 83 ± 5 years). It highlighted a significant association between comorbidities score (assessed by the Cumulative Illness Rating Scale for Geriatrics as part of the MPI Multidimensional Prognostic Index) and 12-month mortality. Compared to group 1, MPI groups 2 and 3 individuals have a higher risk of death (adjusted HR 1.56 [95% CI 1.70–2.09] and 1.72 [1.33–2.22], respectively).Article 2: Frailty and diabetes status in older patients with cancer: impact on mortality in the ANCRAGE cohort. Aging Clin Exp Res. 2020. doi: 10.1007 / s40520-019-01362-9.What is the relationship between diabetes, geriatric oncology frailty and mortality in older cancer patients? In the single-center ANCRAGE cohort, we analyzed the prognostic factors in 1092 elderly subjects with cancer (47% women, mean age 82 ± 5 years), with 20% of diabetic. Frailty prevalence was high in this cohort (84%). During follow-up (median: 15 months [6-29], death in 60%), risk of mortality was higher in patients with diabetes vascular complications (aHR 1.75 [1.15-2.66]), compared to non-diabetic counterparts and whose with diabetes but no VC.Article 3: Diabetes phenotypic characteristics and incident cancer: A cohort approach in French patients with type 2 diabetes - The SURDIAGENE study (manuscript in preparation)Vascular complications increase the progression of cancer and mortality. Yet the relationship between death and diabetes VC has never been explored before in an oncological setting. We focused on the relationship between diabetes VC and cancer: incidence, progression, death. This study in the local SURDIAGENE cohort included 1468 diabetes patients (42% women, mean age 65 ± 11 years, 8% prevalent cancer, 14% incident cancer during the mean follow-up of 7 ± 4 years). Our results confirmed the increased risk of overall mortality in diabetes patients with a past or current history of cancer (n = 313), which was all the more marked in presence of VC (HR 1.73 [1.25-2.38]). Our analyses did not reveal any association between diabetes VC and cancer (prevalent and incident), lymph node and / or metastatic progression, and cancer-related death. There was no relationship between cancer and several plasma biomarkers of metabolic pathways involved in the development of CV: oxidative stress and systemic inflammation.Our results pave the way for improving cancer care in older people with diabetes
David, Hélène. "Le diabète rénal et les glycosuries chez l'adulte jeune". Bordeaux 2, 1990. http://www.theses.fr/1990BOR25203.
Pełny tekst źródłaSangla, Nicole. "Diabète gestationnel : revue de la littérature et étude clinique". Bordeaux 2, 1989. http://www.theses.fr/1989BOR25220.
Pełny tekst źródłaSaulnier, Pierre-Jean. "Étude des déterminants génétiques et environnementaux des complications du diabète de type 2". Thesis, Poitiers, 2012. http://www.theses.fr/2012POIT1403/document.
Pełny tekst źródłaType 2 diabetes (T2D) is a public health issue because of vascular and renal complications, which are complex diseases with interaction between genetic and environmental determinants.The objective of this work was to study these determinants in three independent populations of T2D patients by coupling cross-sectional (DIAB2NEPHROGENE) and longitudinal studies (SURDIAGENE and DIABHYCAR). Through a candidate-gene approach, we first focused on the natriuretic peptides system, NPR3 gene and sodium intake and then on the metabolic pathway of sex hormones, CYP19A1 gene (coding for aromatase) and sex steroid levels.Our first results showed that NPR3 rs2270915 G Allele was associated with high blood pressure (BP) and a reduced salt-sensitivity of BP. However, this SNP was not associated with any significant risk of cardio-vascular events (CVE) or death, at variance with rs6889608. Ultimately, CVE-free survival was impacted by salt intake with a reduced risk of morbi-mortality in those patients having the greatest intake, though a higher BP.In our second study, we confirmed that male gender was a risk factor for diabetic nephropathy (DN), but also for the occurrence of CVE. In men, we showed higher levels of estradiol (E2) associated with a higher prevalence of ND but without any significant increase in renal or CVE during follow-up. CYP19A1 variants were not associated with either E2 levels or the prevalence of ND. However, 2 SNPs tested, were significantly associated with the occurrence of end stage renal failure. Altogether, we have identified 2 different metabolic ways contributing to the genetic determinants of complications associated with T2D including a gene-environment interaction
Lacquemant, Corinne. "Étude génétique de l'insulino-résistance, du diabète et de leurs complications cardio-vasculaires". Lille 1, 2000. https://pepite-depot.univ-lille.fr/LIBRE/Th_Num/2000/50376-2000-322-323.pdf.
Pełny tekst źródłaPar contre, l'incidence des maladies athérosclereuses prématurées a considérablement augmenté ces dernières années a l'île Maurice. Les facteurs de risque généralement associés à cette pathologie sont les anomalies du métabolisme du glucose, des lipides et des facteurs de la coagulation, l'hyperinsulinisme, l'obésité centrale et l'hypertension artérielle. Ce syndrome d'insulinorésistance à une forte composante héréditaire en raison de l'existence d'une forte prévalence de diabète et de maladie coronarienne. L'analyse familiale de liaison dans la population mauricienne nous a permis de détecter des régions liées aux différents facteurs de l'insulinorésistance. D'autres étapes seront nécessaires pour identifier et valider les gènes de prédisposition au développement de ces différentes pathologies
Książki na temat "Prédictions des complications du diabète"
Young, Carolyn. Diabète de type 2. Outremont, Québec: Quebecor, 2003.
Znajdź pełny tekst źródłaDionadji, Mbaïnguinam. Connaître pour mieux vivre le diabète. Ndjaména: CEFOD, 2008.
Znajdź pełny tekst źródłaInternational Working Group on the Diabetic Foot. International consensus on the diabetic foot. Amsterdam: International Working Group on the Diabetic Foot, 1999.
Znajdź pełny tekst źródłaH, Barnett Anthony, red. Diabetes: Best practice & research compendium. Edinburgh: Elsevier, 2006.
Znajdź pełny tekst źródłaMonnier, Louis, i Carole Fumat. Diabétologie. Issy-les-Moulineaux: Elsevier Masson, 2010.
Znajdź pełny tekst źródłaDialysis-Workshop (24th 1988 Prien am Chiemsee, Germany). Diabetes and the kidney. Redaktorzy Heidland August, Koch K. M i Heidbreder E. Basel: Karger, 1989.
Znajdź pełny tekst źródłaCohen, Margo P. The polyol paradigm and complications of diabetes. New York: Springer-Verlag, 1987.
Znajdź pełny tekst źródłaPredine-Hug, François. L'odontologiste face à: Asthme, cirrhose, diabète, endocardite, épilepsie, grossesse, hémophilie, insuffisance cardiaque, AAP, AC, SIDA, toxicomanies : conduites à tenir. Paris: Éd. SID-Groupe EDP sciences, 2011.
Znajdź pełny tekst źródłaTrisha, Dunning, i Ward Glenn MBBS, red. Managing clinical problems in diabetes. Oxford: Blackwell Pub., 2008.
Znajdź pełny tekst źródłaTuch, Bernard. Diabetes research: A guide for postgraduates. Australia: Harwood Academic, 2000.
Znajdź pełny tekst źródłaCzęści książek na temat "Prédictions des complications du diabète"
Orban, J. C., i C. Ichai. "Complications métaboliques aiguës du diabète". W Désordres métaboliques et réanimation, 347–60. Paris: Springer Paris, 2011. http://dx.doi.org/10.1007/978-2-287-99027-4_17.
Pełny tekst źródła"Complications du diabète". W Méga Guide STAGES IFSI, 532–35. Elsevier, 2015. http://dx.doi.org/10.1016/b978-2-294-74529-4.00166-x.
Pełny tekst źródłaAlexandre, J., A. Balian, L. Bensoussan, A. Chaïb, G. Gridel, K. Kinugawa, F. Lamazou i in. "Complications du diabète". W Le tout en un révisions IFSI, 481–84. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70633-2.50165-7.
Pełny tekst źródłaBonnet, F. "Diabète et complications hépatiques". W Diabetologie, 345–51. Elsevier, 2019. http://dx.doi.org/10.1016/b978-2-294-75889-8.00013-0.
Pełny tekst źródłaGuilmot, J. L., N. Ferreira Maldent i J. Magnant. "Complications Vasculaires du Diabète". W Traité de médecine vasculaire., 541–52. Elsevier, 2011. http://dx.doi.org/10.1016/b978-2-294-71346-0.50028-8.
Pełny tekst źródłaBuse, John B. "Prévention et traitement des complications du diabète". W Médecine interne de Netter, 327–33. Elsevier, 2011. http://dx.doi.org/10.1016/b978-2-294-70951-7.00040-2.
Pełny tekst źródłaBORDIER, L., B. BAUDUCEAU, G. DEFUENTES, J. MARGERY, G. DUMAS, G. PETIT-AUBERT, O. DUPUY i in. "Le diabète dans les armées". W Médecine et Armées Vol. 44 No.3, 211–15. Editions des archives contemporaines, 2016. http://dx.doi.org/10.17184/eac.6809.
Pełny tekst źródłaBriet, C., i I. Allix. "Dépistage des complications du diabète de type 1 chez l’enfant". W Diabétologie de L'enfant, 247–56. Elsevier, 2018. http://dx.doi.org/10.1016/b978-2-294-74942-1.00016-1.
Pełny tekst źródła